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The highly conserved 70 kDa heat shock proteins
(Hsp70) play an integral role in proteostasis such
that dysregulation has been implicated in numerous
diseases. Elucidating the precise role of Hsp70 family
members in the cellular context, however, has been
hampered by the redundancy and intricate regulation
of the chaperone network, and relatively few selec-
tive and potent tools. We have characterized a natu-
ral product, novolactone, that targets cytosolic and
ER-localized isoforms of Hsp70 through a highly
conserved covalent interaction at the interface be-
tween the substrate-binding and ATPase domains.
Biochemical and structural analyses indicate that
novolactone disrupts interdomain communication
by allosterically inducing a conformational change
in the Hsp70 protein to block ATP-induced substrate
release and inhibit refolding activities. Thus, novolac-
tone is a valuable tool for exploring the requirements
of Hsp70 chaperones in diverse cellular contexts.
INTRODUCTION
The highly conserved 70 kDa heat shock proteins (Hsp70)
are fundamentally responsible for protein homeostasis through
chaperoning normal folding, translocation, and trafficking
events, as well as facilitating disaggregation and degradation
processes. Some paralogs are constitutively expressed (heat
shock cognates, e.g., HSPA8), while others are induced in the
course of the stress response (e.g., HSPA1A/B). In eukaryotes,
there are specialized isoforms found in each cellular com-
partment including the cytosol, endoplasmic reticulum, and
mitochondria.
Behind Hsp70’s protein-folding capabilities is a two-way
allosteric control mechanism that links its nucleotide-binding
domain (NBD) and substrate-binding domain (SBD) (Zuiderweg
et al., 2013). Briefly, a transient interaction of the polypeptide
substrate with Hsp70’s SBD is controlled by the NBD nucleotideChemistry & Biology 22,state; in the ATP-bound state the affinity is low, while ATP hydro-
lysis increases substrate affinity and reduces association and
dissociation rates. The low basal rate of ATP hydrolysis, essen-
tial for Hsp70 chaperone activity, is stimulated by substrate
binding and J-domain cochaperones (Hsp40s), which also aid
substrate trapping. Nucleotide exchange is rate limiting for sub-
strate release, such that nucleotide exchange factors (NEFs)
control the lifetime of the Hsp70-substrate complex. Thus, these
cochaperones are essential to maintain a continuous cycle of
substrate binding, ATP hydrolysis, and substrate release (Mayer
and Bukau, 2005). Despite a detailed understanding of this cycle
in vitro, the precise relationships among the varied and redun-
dant chaperone network components in a complex cellular envi-
ronment are not fully understood.
In multiple diseases including cancer, as well as via neurode-
generation and aging, protein homeostasis becomes disrupted
and inappropriate Hsp70 activity has been implicated as a key
node for modulation. Both the high metabolic requirements of
cancer cells, which stimulate the stress response, and Hsp70-
mediated inhibition of cell death pathways are proposed to in-
crease dependency on chaperones, stimulating efforts to inhibit
Hsp70 function (Goloudina et al., 2012; Garrido et al., 2006;
Beere et al., 2000). In polyglutamine disorders such as Hunting-
ton’s disease, however, stimulating substrate binding to Hsp70
appears more beneficial than inhibition (Wang et al., 2013; Cha-
fekar et al., 2012). Thus, the type of Hsp70 activity modulation
required to alleviate a given disease is context dependent.
Understanding the precise role of Hsp70s in the cell is chal-
lenging due to the extensive redundancy of the chaperone
network and the negative feedback mechanisms. The conse-
quences of downregulating an individual isoform are limited;
however, dual knockdown of both the cognate and inducible
Hsp70s has been observed to phenocopy Hsp90 inhibition and
cause extensive tumor-selective apoptosis (Powers et al.,
2008; Schlecht et al., 2013). Pharmacological modulation of
Hsp70s can occur within a timeframe that preceeds reequilibra-
tion of the chaperone network; this is a clear benefit, as demon-
stratedwith geldanamycin, to elucidate the precise role of Hsp90
within the cell (Whitesell et al., 1994).
Identification of Hsp70 modulators began with the isolation
of an inhibitory natural product (spergualin and its synthetic de-
rivative, 15-deoxyspergualin) (Nadler et al., 1992). Despite high87–97, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 87
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Novolactone Disrupts Hsp70 Allosteric Regulationhydrophilicity and a high affinity for ATP, twomolecules targeting
the ATP-binding pocket have been described, including an ATP-
competitive inhibitor (VER-155008) (Williamson et al., 2009; Cho
et al., 2011), while two compounds, gentamicin and geranylger-
anylacetone, were reported to block substrate binding with low
potency (Otaka et al., 2007; Yamamoto et al., 2010). In contrast,
sites outside the ATP- and peptide-binding pockets have ap-
peared more druggable. An analog of 15-deoxyspergualin,
MAL3-101, and myricetin inhibit only J-domain-stimulated
ATPase activity of Hsp70, suggesting binding outside the ATP-
binding pocket (Chang et al., 2011; Fewell et al., 2004). MKT-
077 also binds outside the nucleotide-binding pocket but only
in the ADP-bound state (Rousaki et al., 2011), while an additional
set of dihydropyrimidine derivatives, which stimulate or inhibit
Hsp70, also have been described to bind adjacent to the J-
domain binding site (Wise´n and Gestwicki, 2008; Wise´n et al.,
2010). Binding sites in the SBD outside the peptide-binding
pocket were proposed for pifithrin-m (Leu et al., 2009); however,
specific saturable binding was not observed in a biochemical
study (Schlecht et al., 2013). A recent systematic approach to
identify inhibitor-binding sites used a theoretical homology
model of human Hsp70 (Rodina et al., 2013). This strategy
was validated by the identification of allosteric inhibitors that
bound to a pocket in the NBD (Kang et al., 2014; Taldone
et al., 2014). Although a number of the binding sites have been
revealed, a clear mechanistic understanding of the mode of inhi-
bition has not been achieved for most of the above-mentioned
compounds.
Here, we identify and characterize a fungal metabolite, novo-
lactone, which uses a mechanism to disrupt the allosteric regu-
lation of Hsp70 proteins. The covalent means of inhibition as well
as its potency make novolactone a valuable tool to dissect and
elucidate the role of cytoplasmic and ER Hsp70s in the cellular
chaperone network.
RESULTS
Genome-wide Studies in Yeast Identify a Natural
Product that Modulates Hsp70
The genetic tractability and evolutionary conservation of
S. cerevisiae has enabled development of a powerful chemoge-
nomic profiling approach to identify the pathways modulated
by small molecules in a complex cellular environment (Smith
et al., 2010; Hoepfner et al., 2014). Briefly, a pool of heterozygous
or homozygous deletion strains entailing the 6,000 genomic
open reading frames is treated with the compound of interest.
The sensitivity of each strain to the compound compared to the
pool is plotted relative to the statistical sensitivity of that strain
across thousands of chemically diverse scaffolds (Z score). In
the simplest case of a classic enzymatic inhibitor, the single strain
in the haploinsufficient pool (haploinsufficient profiling [HIP]
assay) that represents the molecular target of that compound is
more sensitive and, thus, shows a growth disadvantage. A sec-
ond assay (homozygous profiling [HOP] assay) uses the homozy-
gousdeletions of thenonessential genes and, in a similarmanner,
can provide insight into the compensating pathways and/or syn-
thetic lethal interactions with the compound target.
Novolactone was identified as a potential modulator of the
chaperone network with an unprecedented profile among88 Chemistry & Biology 22, 87–97, January 22, 2015 ª2015 Elsevier3,700 compounds evaluated (Figure 1A). In the HIP assay, het-
erozygous strains sensitive to the compound include ScHsp70,
an Hsp70 NEF (SSE1), a ScHsp90 cochaperone (CNS1), and
the stress-induced heat shock factor (HSF1) (Figure 1B). Several
additional chaperone network components are sensitive in
the HOP assay, including the Hsp90 cochaperones, STI1 and
CPR7, and theprotein disaggregase,HSP104.Cellular processes
that rely heavily on the chaperone network are highlighted in both
the HIP and HOP assays, including nuclear transport (NUP145,
NUP85, and HEH2), the prefoldin complex (GIM5), and ER
translocation (SEC66), further supporting the hypothesis that no-
volactone inhibits a key node. Importantly, the HIP HOP profile of
novolactone is distinct from that of Hsp90 inhibitors, suggesting
that Hsp90 is not the molecular target (Figures 1C and 1D).
In an independent approach, randomly mutagenized haploid
yeast strains resistant to inhibitory concentrations of novolac-
tone were characterized. Screening a genomic library prepared
from one clone identified SSA1, one of four cytoplasmic mem-
bers of the Hsp70 family. The remaining mutants yielded eight
discrete amino acid alterations in SSA1, and representative
strains for each demonstrated 2- to 8-fold resistance to novolac-
tone compared to the unmutated parental strain (Figure 1E).
Expression of representative SSA1 mutations in the parental
yeast strain recapitulated the resistance, indicating a dominant
mechanism (Figure 1F). Interestingly, all mutations caused single
amino acid replacements in the SBD of the Hsp70 protein (Fig-
ure 1G). Taken together, these yeast-based unbiased genome-
wide approaches clearly identify the Hsp70 protein family as a
potential molecular target for novolactone.
Novolactone Irreversibly Inhibits HSP40-Stimulated
Activities of Hsp70 In Vitro
To evaluate whether novolactone affects Hsp70 function, we as-
sessed the impact on substrate refolding in vitro. Heat-dena-
tured firefly luciferase was refolded in the presence of human
Hsp70 (HSPA1A), the J-domain cochaperone HSP40 (DNAJB1),
the NEF APG-2 (HSPH2/HSPA4), and novolactone over time. As
shown in Figure 2A, there was a clear dose-dependent effect of
novolactone on luciferase refolding with a maximal inhibition of
90%.
To elucidate how novolactone inhibits HSPA1A chaperone
activity, we next evaluated the effect on steady-state ATPase
activity in the absence and presence of HSP40 (Figure 2B). Sur-
prisingly, in the absence of HSP40, novolactone stimulated the
steady-state ATPase activity of HSPA1A in a dose-dependent
manner to amaximum level of 1.8-fold the activity in the absence
of compound. In the presence of HSP40, however, novolactone
inhibited the steady-state ATPase activity by 70% (IC50 of
0.25 mM). A similar inhibition was observed with a 10:1 ratio of
HSP40:HSPA1A, suggesting that novolactone inhibits HSP40-
dependent ATPase activity, but is not competitive with HSP40.
As inhibition could be mediated through competition with ATP,
the effect of novolactone was assessed in the presence of
increasing ATP concentrations. Inhibition of ATPase activity re-
mained unchanged, indicating the compound does not compete
with ATP (Figure 2C) and consistent with its stimulatory effect in
the absence of HSP40. Interestingly, the ATPase activity was
inhibited to a lesser degree (70%) compared to the refolding
activity (90%).Ltd All rights reserved
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Figure 1. Genome-wideYeast Assays Impli-
cate Hsp70 Proteins as the Target of Novo-
lactone
(A) Novolactone structure.
(B) Two independent HIP and HOP profiling ex-
periments of novolactone are plotted using sta-
tistical significance of relative strain sensitivity
(Z score, see Experimental Procedures). Strains
essential for viability (gray boxes) and nonessential
(black circles) are indicated. Commonly affected
deletion strains involving chaperone networks are
highlighted.
(C) Comparison of the HIP HOP Z scores for gel-
danamycin and radicicol indicate both Hsp90 in-
hibitors have similar chemogenomic profiles.
(D) The lack of alignment of the novolactone HIP
HOP profile (Z score) with that of geldanamycin
indicates the compounds have different molecular
targets.
(E) Isolated genomic mutants are less sensitive to
novolactone compared to the parental strain at the
peak of logarithmic growth (16 hr). Individual
strains were grown in rich media in a dose
response of the compound. A representative data
set from three technical replicates is shown.
(F) The mutations confer a dominant phenotype.
Mutated SSA1 expressed from a plasmid trans-
formed into wild-type cells led to resistance to
novolactone (1.5 mM). Representative data set
from at least two independent replicates is shown.
(G) Hsp70 domain architecture with SSA1
numbering. Resistant mutations (black lines)
localized to the b sandwich domain.
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Novolactone Disrupts Hsp70 Allosteric RegulationThe kinetics of novolactone inhibition of the ATPase activity
was assessed after preincubating the compound with HSPA1A
for 0, 30, or 60 min (Figure 2D). Remarkably, a 30 min preincuba-
tion led to a significant increase (5- to 10-fold) in novolactone po-
tency, although the residual ATPase activity (30%) remained
unchanged with longer incubations. We assessed the revers-
ibility of the time-dependent inhibition by preincubating HSPA1A
(60 min) with a 10-fold molar excess of novolactone to allow full
complex formation. Excess compound was removed by gel
filtration and the compound-protein complex was diluted to pro-
mote dissociation, prior to evaluating the ATPase activity recov-
ery. The time course of ADP production was linear and did not
follow a model for reversible inhibition (recovery fit), indicating
that ATPase activity did not increase over time as would be
expected in a dissociation of the compound-protein complexChemistry & Biology 22, 87–97, January 22, 201(Figure 2E). These data suggest that the
inhibition of HSPA1A’s ATPase activity
by novolactone is irreversible.
Novolactone Inhibits Hsp70
through a Covalent Interaction with
Glu444
The dramatic effect of preincubation
and the irreversibility of the novolactone
inhibition suggest that the mechanism
involves a covalent interaction. Indeed,
through liquid chromatography-massspectrometry (LC-MS) analysis of the HSPA1A protein in the
presence or absence of novolactone, we could observe a differ-
ence in mass indicative of a covalent adduct (Figure S1A avail-
able online). Importantly, there was no mass difference for BSA
in the presence of novolactone, suggesting a selective covalent
interaction. To characterize the adduct, HSPA1A protein in
the presence or absence of the compound was digested with
proteases and the resulting pattern identified Glu444 as the sin-
gle modification site (Figure S1B). Interestingly, mutation of the
homologous yeast residue (ScSSA1-E441K) was identified as
enabling resistance (see above).
The most likely reactive moiety for covalent adduct formation
in the novolactone structure is the lactone ring. Methanolic treat-
ment opens the ring to form methylnovolactone, which was
observed to bemuch less effective than novolactone in inhibiting5 ª2015 Elsevier Ltd All rights reserved 89
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Figure 2. Novolactone Irreversibly Inhibits
Luciferase Refolding and ATP Hydrolysis
(A) Luciferase-refolding activity of HSPA1A in the
presence of 0 mM (C), 0.3 mM (⁪), 0.6 mM (A),
2 mM (7), 4 mM (:), and 8 mM (-) novolactone.
(B) ATPase activity in response to novolactone in
the absence (C) and presence of 1:1 (-) or 10:1
(:) HSP40.
(C) Novolactone inhibition of ATPase activity in the
presence of 1 mM (C), 10 mM (-), and 50 mM (:)
ATP.
(D) ATPase activity after preincubation with novo-
lactone for 0 min (C), 30 min (-), and 60 min (:).
(E) ATPase activity as a ratio of 620/665 nm of
HSPA1A alone (C) and HSPA1A-novolactone
complex (-) after 60 min preincubation of
HSPA1A with novolactone (10-fold excess) fol-
lowed by removal of unbound compound and 100-
fold dilution in buffer. Solid lines represent linear
fits and the dotted line represents the predicted fit
for recovery of activity resulting from novolactone
dissociation.
(F) ATPase activity in response to methyl-
novolactone in the absence (C) and presence of
1:1 (-) or 10:1 (:) HSP40. Data are means from
three independent experiments; error bars show
the SE.
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Novolactone Disrupts Hsp70 Allosteric RegulationHSPA1A ATPase activity (Figures 2F and S2A). Further, HIP HOP
analysis demonstrated little cellular activity compared to novo-
lactone, confirming the critical role of the lactone ring in medi-
ating the covalent adduct (Figure S2B).
Biochemical Dissection of the Molecular Mechanism of
Novolactone
To clarify the molecular mechanism by which novolactone in-
hibits the HSPA1A chaperone activity, we followed the surprising
observation that novolactone stimulated the basal ATPase rate
but partially inhibited the HSP40-stimulated ATPase rate (Fig-
ure 2B). There are three possibilities for such an effect: (1) novo-
lactone could directly disrupt the interaction of the J-domain
of HSP40 with the NBD of HSPA1A; (2) in the presence of a
J-domain cochaperone, nucleotide exchange becomes rate
limiting for the steady-state ATPase activity of Hsp70s (Brehmer
et al., 2001; Gassler et al., 2001) and inhibition of nucleotide ex-
change would limit the observable HSP40-stimulated ATPase
rate; or (3) novolactone could interfere with the allosteric mech-
anism of HSPA1A. The first hypothesis is unlikely, however,
because complete inhibition of the ATPase activity could not
be achieved even at very high novolactone concentrations,
and there was no competition effect with HSP40 (see above).90 Chemistry & Biology 22, 87–97, January 22, 2015 ª2015 Elsevier Ltd All rights reservedTo test the second hypothesis we
measured the influence of novolactone
on nucleotide exchange by determining
the ADP dissociation rate in the absence
and presence of the APG2 NEF
(Dragovic et al., 2006; Raviol et al.,
2006), using the fluorescent ADP
analog N8-(4N0-methylanthraniloylami-
nobutyl)-8 amino-adenosine 50-diphos-
phate (MABA-ADP) (Theyssen et al.,1996). The measured exchange rates were nearly identical
(Figure 3A), demonstrating that novolactone has no effect on
ADP release. Alternatively, novolactone may directly affect g-
phosphate cleavage; thus, we determined HSPA1A’s ATPase
rate under single-turnover conditions. Complexes of HSPA1A
with ATP were isolated, and in the absence of compound we
measured a basal ATP hydrolysis rate of 3.3 3 104 s1,
consistent with previous observations (Gassler et al., 2001). In
the presence of novolactone, we observed a concentration-
dependent stimulation of this single-turnover ATPase rate by
10% to 40% (Figures 3B and S3), consistent with the steady-
state ATPase assays. The basal single-turnover ATPase rate
was stimulated 78-fold (2.6 3 102 s1) by HSP40, and was
only slightly inhibited upon the addition of novolactone. In the
steady-state ATPase assays, novolactone was more potent af-
ter preincubation with HSPA1A; however, this is not possible
with the HSPA1A ,ATP complexes. Thus, we first incubated
HSPA1A with a 4-fold molar excess of novolactone to form
the covalent adduct and subsequently isolated HSPA1A ,ATP
complexes. Even under these conditions, the HSP40-stimu-
lated ATPase activity was only reduced to 57% of the activity
of the untreated HSPA1A sample, contrasting with the 70%
inhibition seen in the steady-state assay.
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Figure 3. Novolactone Inhibits the Allosteric Control Mechanism of
HSPA1A
(A) Novolactone influences neither basal (gray bars) nor APG2-stimulated
(black bars) nucleotide exchange rates. Nucleotide exchange was measured
in the absence and presence of novolactone (I, +4 mM I) by following the
change in fluorescence of the fluorescent ADP analog MABA-ADP (Theyssen
et al., 1996). Traces were fitted by single-exponential decay functions.
(B) Novolactone partially inhibits HSP40-stimulated rate of g-phosphate
cleavage. ATPase activity was measured under single-turnover conditions in
the absence (gray bars) or presence of HSP40 (black bars), absence or
presence of novolactone (I, +8 mM I), and with HSPA1A ,ATP complexes that
were isolated from novolactone-pretreated HSPA1A (HSPA1A ,I complex).
(C) Novolactone prevents the stimulation of substrate release by ATP. Sub-
strate dissociation was measured in the absence (gray bars) and presence of
ATP (black bars) and absence and presence of novolactone (I, +4 mM I) by
following the decrease of fluorescence of a fluorescent-labeled peptide
(dansyl-NRLLLTG). Traces were fitted by single-exponential decay functions.
Error bars represent the SE of two to four experiments.
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Novolactone Disrupts Hsp70 Allosteric RegulationIt was shown previously that full stimulation of the ATPase ac-
tivity of Hsp70s requires the synergistic action of a J-domain pro-
tein and a substrate (Karzai and McMacken, 1996; Barouch
et al., 1997), but that some J-domain proteins can deliver both
signals in the absence of a substrate by interacting simulta-Chemistry & Biology 22,neously with the NBD and the SBD (Laufen et al., 1999). Further-
more, full stimulation of the ATPase activity requires an intact
interdomain communication between the NBD and SBD. We hy-
pothesized that the effect of novolactone on the HSP40-stimu-
lated ATPase activity could be explained by an interference
with this interdomain communication, and evaluated the effect
on ATP-stimulated peptide release (Figure 3C). In the absence
of ATP, peptides dissociate from HSPA1A at a rate of 1.2 3
103 s1, and novolactone had little effect on this parameter.
ATP stimulates this rate by more than three orders of magnitude
to 6.6 s1; however, in the presence of novolactone, the ATP-
stimulated rate of peptide dissociation was drastically reduced
to 1.5 3 103 s1. Therefore, novolactone increased the half-
life of the HSPA1A-peptide complex 4,500-fold from 0.11 to
471 s. Together these data strongly suggest that novolactone
impairs the allosteric control mechanism between the SBD and
the NBD of HSPA1A.
Structural Analysis of the Hsp70 SBD with Novolactone
To validate this hypothesis and gain insight into the novolac-
tone-binding pocket, we used X-ray crystallography to deter-
mine the structures of the apo (Protein Data Bank [PDB] ID
4WV5) and covalently modified (PDB ID 4WV7) HSPA1A SBD
(395–543) to 2.0 and 2.4 A˚ resolution, respectively. The struc-
tures contained the SBDb subdomain as well as aA and aB
of the SBDa subdomain (Figure 4A; Table S1). The overall
fold of the HSPA1A SBD structure compared well with that of
the previously described DnaK SBD structure (Zhu et al.,
1996), a protein sharing strong homology with HSPA1A, with
an rmsd of 0.503 A˚ when comparing the SBDb subdomains
(residues 395–504). Changes between novolactone-bound
HSPA1A and DnaK SBDs also reflected those seen between
novolactone-bound and apo HSPA1A SBDs. In both HSPA1A
SBD structures the C-terminal portion of helix aB, including
residues Lys539-Glu543, could be seen binding in the sub-
strate-binding pocket, as has been observed previously for
similar structures (Jiang et al., 2005; Morshauser et al., 1999;
Wang et al., 1998).
Comparison of the apo HSPA1A SBD structure to that of the
novolactone-bound revealed a covalent linkage at Glu444
within L4,5 (Figures 4B and 4C). The binding pocket for this
modification was defined by multiple van der Waals interactions
with residues Ala397-Leu399 of b1, Leu456 of b5, Gly484-Ile485
of L6,7, Ile480 of b6, Ile503-Asp506 of La,b, and Leu510 of aA.
Water-mediated hydrogen bonds between the hydroxyl group
of the novolactone and the backbone amide and carbonyl of
Leu399 also were present in the B molecule of the structure.
Further effects of this modification included a repositioning of
b7 and L6,7.
Residues within regions L4,5, L6,7, and b7 of the SBD have
been shown previously to interact at the interface with the
NBD in the ATP-bound open conformation of DnaK (Kityk
et al., 2012; Figure 4D), a region implicated in the allosteric regu-
lation of Hsp70s. The covalent modification of Glu444 would
clearly disrupt this interface (Figures 4E and 4F), including the
loss of a hydrogen bond between its side chain and the back-
bone amide of Asp152 within the IA subunit of the NBD. An addi-
tional hydrogen bond between the backbone amide of Leu486
within L6,7 to the side chain of Asp152 would be lost due to87–97, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 91
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Figure 4. Crystal Structure of HSPA1A with Novolactone
(A) Crystal structure of HSPA1A SBD (gray) covalently modified by novolactone (yellow). The substrate-binding site is occupied by the C terminus of the protein
(magenta).
(B) The unbiased electron density (Fo-Fc omit map contoured at 3s) for novolactone bound to Glu444.
(C) Novolactone-binding site showing covalent modification of Glu444 as well as multiple residues involved in van der Waals interactions.
(D) Overlay of the crystal structures of the HSPA1A SBD (gray) and DnaK in the ATP-bound open conformation (PDB ID 4B9Q) (Kityk et al., 2012), containing both
the NBD (blue) and SBD (cyan).
(E) Binding pocket from overlay showing steric clash between novolactone (yellow) and the NBD (blue) as well as the relocation of b7 and L6,7 in HSPA1A SBD
(gray) compared to the DnaK SBD (cyan).
(F) Binding pocket from overlay showing key interactions between the NBD (blue) and SBD (cyan) of DnaK that would be disrupted upon novolactone binding.
Residue numbering is for HSPA1A with the equivalent DnaK residue in parentheses.
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Novolactone Disrupts Hsp70 Allosteric Regulationthe repositioning of this loop away from the NBD as well as steric
interference of novolactone. Additionally, hydrogen bonding in-
teractions between Asn483 within L6,7 to the backbone amide
of Ile172 and from its backbone amide to the Arg155 side chain
in the NBD would be disrupted. The equivalent residue in DnaK
(Arg151) has been defined as a relay in determining the confor-
mation of the SBD (Vogel et al., 2006a). Notably, the residues
surrounding the compound-binding pocket in the crystal struc-
ture are homologs to those identified in the yeast mutagenesis
approach (see above).
Recently, a crystal structure of the DnaK SBD in complex
with a noncovalently interacting molecule, PET-16, was re-
ported (Leu et al., 2014). Although much of PET-16 is solvent
exposed, an acetylene linker directs a phenyl group into a
portion of the binding pocket occupied by novolactone, sup-
porting the potential for druggability. Importantly, aside from
the results presented here, a comprehensive demonstration
that a small molecule bound in this pocket disturbs the allo-
steric communication between NBD and SBD has not been
reported previously.92 Chemistry & Biology 22, 87–97, January 22, 2015 ª2015 ElsevierNovolactone Is Selective for Cytosolic and ER-Localized
Isoforms of Hsp70
We noted that the key interacting residues of novolactone, as
identified by yeast mutagenesis and visualized by cocrystalliza-
tion with the SBD, are conserved across both human and yeast
species. Interestingly, the Glu444-binding site is a glutamine in
all ribosome-associated and mitochondrial isoforms of Hsp70
(Figure S4). When this subtle substitution was introduced in
the yeast SSA1 (E441Q), sensitivity to novolocatonewas dramat-
ically decreased (Figure 1F), indicating the compound is likely
active against all cytosolic and ER-localized Hsp70 family mem-
bers, but not ribosome-associated or mitochondrial isoforms.
To evalute this hypothesis, we took advantage of the yeast
genetic malleability to generate a strain missing the redundant
cytoplasmic Hsp70 isoforms (Dssa2-4). In this background
compared to one with an intact chaperone network, there was
an additional decrease in sensitivity for the SSA1-E441Q mutant
(Figure 5). When the novolactone target residue in the ER-local-
ized Kar2 was additionally mutated to a glutamine (E487Q), there
was nearly a 100-fold shift in sensitivity compared to a wild-typeLtd All rights reserved
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Figure 5. Sensitivity to Novolactone Requires Intact Cytosolic or ER-
Localized Hsp70s
Yeast strains missing redundant cytosolic Hsp70s (Dssa2-4) and/or express-
ing Hsp70s missing the novolactone-reactive glutamine (cytosolic, SSA1-
E441Q; ER-localized, KAR2-E487Q) were grown in rich media with compound
dilutions. A representative data set with biological duplicates from two tech-
nical replicates is shown.
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Novolactone Disrupts Hsp70 Allosteric Regulationcontrol. The residual activity of novolactone in this cellular
context was similar to that of methylnovolactone on HSPA1A
in vitro (Figure S2B), and may be attributed to a noncovalent
interaction with the protein. Taken together, these data demon-
strate that novolactone is selectively reactive against cytosolic
and ER-localized Hsp70 family members.
Novolactone Disrupts Hsp70 Protein Function in
Mammalian Cells
The chemogenomic profiling indicates novolactone affects the
chaperone network in yeast, and, while the compound inhibits
the human HSPA1A in vitro, we wanted to evaluate whether it
has a selective effect on Hsp70s in mammalian cells. Novolac-
tone was tested in human cells alongside an ATP-competitive
inhibitor of Hsp70s, VER-155008, and the Hsp90 inhibitor,
HSP990, for comparison (Figure 6A; Williamson et al., 2009; Me-
nezes et al., 2012). In cells, Hsp70s and Hsp90s cooperate in the
folding of several key regulatory proteins; thus, their activities are
highly connected. We selected two lung cancer cell lines that
express the known HSP90 client proteins EGFR and MET: (1)
EBC-1 (EGFR wild-type, MET amplified), and (2) HCC827
(EGFR oncogenic E746-A750 deletion, MET wild-type). Treat-
ment of either cell line with HSP990 led to increased degradation
of EGFR andMETproteins, aswell as stimulation of HSPA1A and
c-PARP, a marker of apoptosis, consistent with previous reports
(Figure 6A; Menezes et al., 2012). In comparison, VER-155008
had little effect on these Hsp90 client proteins, but at higher
concentrations stimulated c-PARP and HSPA1A. Novolactone
treatment led to reduced levels of Hsp90 client proteins and in-
duction of both HSPA1A and c-PARP. This pattern of events
resembled that seen with the Hsp90 inhibitor, but also was
consistent with inhibition of both HSPA1A and HSPA8 (Powers
et al., 2008). No covalent adduct was observed upon incubation
of novolactone with purified HSP90AB1 (Figure S5), and the ef-
fect was consistent with inhibition of all cytosolic forms of the
Hsp70s, as predicted by the reactivity of novolactone. Further,Chemistry & Biology 22,the induction of HSPA1A would simply reflect the novolactone-
mediated inhibition of HSPA8.
To confirm the reactivity of novolactone with both isoforms of
mammalian Hsp70, we utilized an HCT116 cell line generated to
inducibly knock out HSPA8. As expected, HSPA1A was clearly
upregulated in response to HSPA8 inactivation (Figure 6B;
compare WT to HSPA8/fl). In the presence of novolactone,
the depletion of Hsp90 client proteins (HER2 and CDK4) was
significantly enhanced when combined with the HSPA8
knockout (Figure 6C). Thus, the response profile of novolactone
in mammalian cells is consistent with a selective inhibition of
both the inducible and constitutive Hsp70 proteins in the chap-
erone network.
DISCUSSION
Using a combination of cellular and in vitro approaches, we have
identified and characterized the natural product, novolactone, as
having an unprecedented ability to affect the cellular chaperone
network through allosterically blocking interdomain communica-
tion and, consequently, ATP-induced substrate release by cy-
tostolic and ER-localized Hsp70 proteins.
To understand the functional consequences of the covalent
adduct, it is important to appreciate that Hsp70s undergo dra-
matic conformational changes when progressing through the
ATPase cycle (Figure 7A). In the nucleotide-free state, the NBD
and SBD are connected only by a flexible linker. Upon ATP bind-
ing by the NBD, the SBD dissociates into the b sandwich subdo-
main and the a-helical lid subdomain and docks onto two faces
of the NBD. Glu444 is exactly at the interface between the b
sandwich subdomain and the NBD, and the novolactone adduct
induces a conformational change that appears incompatible
with the interaction of the two domains (Figure 4E). The contacts
between the b sandwich subdomain and the NBD are essential
to induce the opening of the substrate-binding cleft and sub-
strate release (Figure 7A), as has been shown in several studies
(Jiang et al., 2005; Liu and Hendrickson, 2007; Montgomery
et al., 1999; Smock et al., 2010; Vogel et al., 2006a).
The disruption of interdomain communication also explains
two observations that initially seemed odd. First, novolactone
increased the basal ATPase rate in steady-state and single-turn-
over experiments (Figures 2B, 3B, and S3). All known single
amino acid replacement variants of Hsp70s, at the interface be-
tween the b sandwich subdomain of the SBD and the NBD and
that block interdomain communication, also have an increased
basal rate of ATP hydrolysis (Montgomery et al., 1999; Smock
et al., 2010; Vogel et al., 2006a, 2006b). These observations sug-
gest that a functional interdomain communication is required for
the low basal ATPase activity of Hsp70s. This is also consistent
with a recent nuclear magnetic resonance (NMR) study, which
suggested that the hydrolysis competent conformation of
Hsp70s is only reached by a tug-of-war between the b sandwich
subdomain and NBD (Zhuravleva et al., 2012).
The second puzzling observation was that novolactone in-
hibited the HSP40-stimulated ATPase rate in steady-state
ATPase assays by 70%,while the inhibition in single-turnover as-
says was less than 50% evenwhen nearly 100%of HSPA1Awas
modified, as verified by mass spectrometry (MS) (Figure S1). In
steady-state assays, a new ATP must bind after hydrolysis to87–97, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 93
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Figure 6. Novolactone Treatment of Cancer
Cells Leads to Hsp90-Inhibitor-like Down-
stream Effects
(A) EBC-1 (EGFR wild-type, MET amplified) and
HCC827 (EGFR oncogenic E746-A750 deletion,
MET wild-type) cells were treated with an Hsp90
inhibitor (HSP990), an ATP competitive inhibitor of
Hsp70s (VER-155008), or with novolactone.
Western analysis of EGFR, c-PARP, HSP70, and
GAPDH after 24 hr treatment.
(B) Western analysis of HSPA8 and HSPA1A at
different time points after HSPA8/fl HCT116 cells
were transduced with CRE adenovirus.
(C) Western analysis of ERBB2 and CDK4 3 days
after HSPA8/fl HCT116 cells were transduced
with CRE adenovirus, then followed by 24 hr of
treatment with serial dilutions of novolactone.
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Novolactone Disrupts Hsp70 Allosteric Regulationenable the next round of hydrolysis. The ATP binding occurs via a
two-step mechanism that, for reasons not yet understood, re-
quires substrate release before a hydrolysis-competent confor-
mation can be assumed. Under these conditions, HSP40 is
able to provide both signals necessary for triggering ATP hydro-
lysis in HSP70; the J-domain interacts with the NBD, and a re-
gion C-terminal to the J-domain acts as the substrate. As we
have shown here, however, novolactone blocked the ATP-stim-
ulated substrate release. Therefore, HSP40 dissociation (i.e.,
substrate release) prior to rebinding to trigger the second round
of ATP hydrolysis was likely the rate-limiting step in steady-state
ATPase assays. In single-turnover assays, HSP40 dissociation
and rebinding was not necessary, explaining the reduced impact
of novolactone.
The initial binding of novolactone for the Hsp70-binding
pocket seems to be driven by a series of noncovalent interac-
tions, which enables proper positioning of the compound. The
lactone is the key reactive moiety of novolactone, and it likely un-
dergoes an irreversible transesterification reaction with the car-
boxylic acid of Glu444 (Figure 7B). The resulting stable ester
bond would subsequently induce or stablize a change in confor-
mation, forcing the Hsp70 protein to adopt a nonfunctional state.
One can envisage two scenarios to explain the long preincuba-
tion time required for maximal inhibitory activity: (1) it may take
time for the compound to be properly positioned to enable the
covalent reaction, or (2) the covalent interaction induces a
conformational change that takes time to have functional effects.
ScHsp70 (SSA1) was identified as the primary target of novo-
lactone in a cellular context using unbiased genome-wide muta-
genesis, while cocrystallization of HSPA1A and novolactone
yielded unequivocal identification of Glu444 as the site of cova-
lent modification. Sequence comparisons suggested that cyto-
plasmic and ER-localized isoforms were targets of novolactone.94 Chemistry & Biology 22, 87–97, January 22, 2015 ª2015 Elsevier Ltd All rights reservedThis was confirmed in yeast where, upon
accounting for the redundancy of the
cytosolic Hsp70s, substitution of the
reactive glutamate in the remaining pro-
teins was sufficient to dramatically shift
the sensitivity to novolactone. Inmamma-
lian cells, novolactone stimulated deple-
tion of Hsp90 client proteins and inducedapoptosis, a selective and relevant response demonstrating the
applicability of the compound to mammalian systems.
Selective pharmacological inhibitors can be extremely useful
in dissecting the precise role of individual chaperones within
the cellular chaperone network. While several compounds
have been reported to bind and inhibit Hsp70s, novolactone is
one of the fewwhere themechanism of action has been compre-
hensively delineated at both the molecular level and in a cellular
environment. Novolactone is, thus, a valuable tool for evaluating
Hsp70 as a potential drug target in different cellular contexts
(Frye, 2010).
SIGNIFICANCE
The Hsp70 protein family plays an integral role in proteosta-
sis and, as such, has been implicated as a key node in
numerous diseases. There remains some uncertainty as to
how the pathway should be modulated, however, as benefit
has been reported with both stimulation and/or inhibition of
Hsp70 in various disease contexts. One of the greatest
challenges to deconvoluting the role in the cellular chap-
erone network is the extensive reduncancy and intricate
regulation of Hsp70s, which inherently limit the application
of genetic tools. We have characterized a natural product,
novolactone, which can assist in determining the require-
ments of cytosolic and ER-localized Hsp70s under different
conditions. Novolactone covalently binds a discrete residue
(Glu444) at the interface of the SBD and the NBD to inhibit
substrate-folding activities through a novel allosteric mech-
anism. The observed increase in ATP hydrolysis upon
novolactone treatments also validates current models of
Hsp70 interdomain regulation with critical interactions be-
tween the b sandwich subdomain and NBD. Further, the
ADP ATP
Pi
HSP40
APG-2
slow
fast
substrate ATP
ADP ATP
Novolactone
Pi
A
OH
HO
O
O
H
H
H
Novolactone
COOH
E444
HSP70-bound
OH
HO
H
H
H
OH
HO
H
H
H
HO
O
Novolactonic acid
OE444
O
HO
O
HO
H2O
B
Figure 7. Mode of Action of the Hsp70 Inhib-
itor, Novolactone
(A) Hsp70s undergo several distinct conformational
changes while progressing through the ATPase
cycle. In the ADP-bound state substrate associa-
tion and dissociation rates are low. After AGP-2-
stimulated ADP dissociation, ATP binding to the
NBD leads todockingof theb sandwich subdomain
of the SBD to the NBD with subsequent opening of
the substrate-binding pocket. Novolactone binding
interferes with the interaction of the b sandwich
domain with the NBD and, thus, disturbs the allo-
steric opening of the substrate-binding cleft. The
HSP40-mediated stimulation of the ATPase activity
is also strongly reduced (red dotted arrow).
(B) Proposed reactivity of novolactone. Under
physiological conditions, the lactone degrades to
the free acid (left), which, like methylnovolactone,
would be essentially inactive. In the proximity of
Glu444, however, transesterification is favored
resulting in covalent bond formation with the
protein (right).
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Novolactone Disrupts Hsp70 Allosteric Regulationconservation of the novolactone-binding pocket from hu-
mans to yeast cytosolic and ER-localized Hsp70 isoforms
provides versatility for potential applications.
EXPERIMENTAL PROCEDURES
HIP HOP Assay
TheHIPHOP assay andmicroarray analysis were performed as described pre-
viously (Pierce et al., 2007).
Yeast Strains
A BY4743 strain containing deletions of multiple drug resistance genes (D8 -
snq2::KanMX; pdr5::KanMX; pdr1::NAT1; pdr3::KanMX; yap1::NAT1; pdr2D;
yrm1D; yor1D) was used for all experiments and modified further as needed
using standard techniques.
ATPase Assay
ATP (1 mM) and HSP40 were mixed together and reaction was initiated with
addition of HSPA1A at the desired concentration in reaction conditions of
50 mM HEPES, pH 7.3, 10 mM MgCl2, 20 mM KCl, 2 mM TCEP, and 0.01%
BSA. The reaction was stopped with ADP-Glo, and ADP detection reagent
(Promega) was added prior to reading luminescence with the EnVision plate
reader (Perkin Elmer). For determining dissociation kinetics, a 10-fold excess
of novolactone was incubated with HSPA1A for 60 min prior to removal of un-
bound compound and 100-fold dilution of the HSPA1A-novolactone complex
in reaction buffer. Equal proportions of the complex (40 nM) was mixed with
ATP (20 mM), 400 nM HSP40, and 1% DMSO in reaction buffer, and the
ATPase activity was monitored using the HTRF Transcreener ADP detection
kit (Cisbio).
Single-Turnover ATPase Assay
HSPA1A ATPase activity under single-turnover conditions in the absence and
presence of HSP40 (2 mM) was determined as described previously (Mayer
et al., 1999).Chemistry & Biology 22, 87–97, January 22, 201Substrate Dissociation Kinetics
Substrate dissociation kinetic measurements, in
the presence and absence of ATP,were performed
as described previously (Gassler et al., 2001).
Nucleotide Exchange Kinetics
Nucleotide exchange kinetic measurements were
performed as described previously (Gassleret al., 2001), except that APG2 was used as an NEF. When appropriate,
HSPA1A was preincubated with novolactone.
Luciferase-Refolding Assay
Firefly luciferase was mixed with HSPA1A, HSP40, and APG2 and thermally
denatured at 42C. At given time points after shifting the reaction to 30C, al-
iquots were mixed with luciferin and luminescence was measured in a Bio-
lumat (Berthold). Where appropriate, novolactone was added to the reaction
prior to unfolding.
Covalent Modification and MS
For intact MS, novolactone (10-fold excess) was incubated with a mixture of
HSPA1A and BSA at room temperature for 60min. Before and after compound
treatment, an aliquot was analyzed on a Waters Micromass ZQ mass spec-
trometer. For tandem mass spectrometry (MS/MS) analysis, samples were
treated with LysC (Roche), both LysC and AspN (Roche), or trypsin enzyme
at room temperature overnight. Concentrated protein digests were then
analyzed by LC-MS with an Agilent 1200 capillary LC stack using an Acquity
BEH C-18 1.0 3 100 mm chromatography column and a Thermo Scientific
LTQ mass spectrometer. Mascot software was used for data analysis.
Compounds
Novolactone has been isolated as a secondary metabolite of a fungal strain
closely related to Aporospora terricola. Methylnovolactone was generated
by dissolving novolactone in methanol for 5 days and subsequently purified
by reverse-phase chromatography. Structure elucidation was achieved by
means of ESI-MS as well as 1D and 2D NMR spectroscopy.
Additional details are included in theSupplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.chembiol.2014.11.007.5 ª2015 Elsevier Ltd All rights reserved 95
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